Global Neuromyelitis Optica Drug Supply, Demand and Key Producers, 2024-2030

Description

The global Neuromyelitis Optica Drug market size is expected to reach $ 59 million by 2030, rising at a market growth of 2.9% CAGR during the forecast period (2024-2030).

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

This report studies the global Neuromyelitis Optica Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Neuromyelitis Optica Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neuromyelitis Optica Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Neuromyelitis Optica Drug total market, 2019-2030, (USD Million)
Global Neuromyelitis Optica Drug total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Neuromyelitis Optica Drug total market, key domestic companies and share, (USD Million)
Global Neuromyelitis Optica Drug revenue by player and market share 2019-2024, (USD Million)
Global Neuromyelitis Optica Drug total market by Type, CAGR, 2019-2030, (USD Million)
Global Neuromyelitis Optica Drug total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Neuromyelitis Optica Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork and Baxter, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neuromyelitis Optica Drug market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Neuromyelitis Optica Drug Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Neuromyelitis Optica Drug Market, Segmentation by Type
    Glucocorticoids
    Immunotherapies
    Others

Global Neuromyelitis Optica Drug Market, Segmentation by Application
    Acute Attack
    Remission Prophylactic Treatment

Companies Profiled:
    Pfizer
    Fresenius
    Teva
    Sandoz
    Intas
    Gyjtrs
    NANG KUANG
    Tianjin Kingyork
    Baxter
    CSL
    Grifols
    Octapharma
    CBOP

Key Questions Answered
1. How big is the global Neuromyelitis Optica Drug market?
2. What is the demand of the global Neuromyelitis Optica Drug market?
3. What is the year over year growth of the global Neuromyelitis Optica Drug market?
4. What is the total value of the global Neuromyelitis Optica Drug market?
5. Who are the major players in the global Neuromyelitis Optica Drug market?

Table of Contents

1 Supply Summary
    1.1 Neuromyelitis Optica Drug Introduction
    1.2 World Neuromyelitis Optica Drug Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Neuromyelitis Optica Drug Total Market by Region (by Headquarter Location)
        1.3.1 World Neuromyelitis Optica Drug Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Neuromyelitis Optica Drug Market Size (2019-2030)
        1.3.3 China Neuromyelitis Optica Drug Market Size (2019-2030)
        1.3.4 Europe Neuromyelitis Optica Drug Market Size (2019-2030)
        1.3.5 Japan Neuromyelitis Optica Drug Market Size (2019-2030)
        1.3.6 South Korea Neuromyelitis Optica Drug Market Size (2019-2030)
        1.3.7 ASEAN Neuromyelitis Optica Drug Market Size (2019-2030)
        1.3.8 India Neuromyelitis Optica Drug Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Neuromyelitis Optica Drug Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Neuromyelitis Optica Drug Major Market Trends

2 Demand Summary
    2.1 World Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.2 World Neuromyelitis Optica Drug Consumption Value by Region
        2.2.1 World Neuromyelitis Optica Drug Consumption Value by Region (2019-2024)
        2.2.2 World Neuromyelitis Optica Drug Consumption Value Forecast by Region (2025-2030)
    2.3 United States Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.4 China Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.5 Europe Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.6 Japan Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.7 South Korea Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.8 ASEAN Neuromyelitis Optica Drug Consumption Value (2019-2030)
    2.9 India Neuromyelitis Optica Drug Consumption Value (2019-2030)

3 World Neuromyelitis Optica Drug Companies Competitive Analysis
    3.1 World Neuromyelitis Optica Drug Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Neuromyelitis Optica Drug Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Neuromyelitis Optica Drug in 2023
        3.2.3 Global Concentration Ratios (CR8) for Neuromyelitis Optica Drug in 2023
    3.3 Neuromyelitis Optica Drug Company Evaluation Quadrant
    3.4 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
        3.4.1 Neuromyelitis Optica Drug Market: Region Footprint
        3.4.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
        3.4.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Neuromyelitis Optica Drug Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Neuromyelitis Optica Drug Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Neuromyelitis Optica Drug Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Neuromyelitis Optica Drug Consumption Value Comparison
        4.2.1 United States VS China: Neuromyelitis Optica Drug Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Neuromyelitis Optica Drug Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Neuromyelitis Optica Drug Companies and Market Share, 2019-2024
        4.3.1 United States Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Neuromyelitis Optica Drug Revenue, (2019-2024)
    4.4 China Based Companies Neuromyelitis Optica Drug Revenue and Market Share, 2019-2024
        4.4.1 China Based Neuromyelitis Optica Drug Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Neuromyelitis Optica Drug Revenue, (2019-2024)
    4.5 Rest of World Based Neuromyelitis Optica Drug Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Neuromyelitis Optica Drug Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Neuromyelitis Optica Drug Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Glucocorticoids
        5.2.2 Immunotherapies
        5.2.3 Others
    5.3 Market Segment by Type
        5.3.1 World Neuromyelitis Optica Drug Market Size by Type (2019-2024)
        5.3.2 World Neuromyelitis Optica Drug Market Size by Type (2025-2030)
        5.3.3 World Neuromyelitis Optica Drug Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Neuromyelitis Optica Drug Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Acute Attack
        6.2.2 Remission Prophylactic Treatment
    6.3 Market Segment by Application
        6.3.1 World Neuromyelitis Optica Drug Market Size by Application (2019-2024)
        6.3.2 World Neuromyelitis Optica Drug Market Size by Application (2025-2030)
        6.3.3 World Neuromyelitis Optica Drug Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Details
        7.1.2 Pfizer Major Business
        7.1.3 Pfizer Neuromyelitis Optica Drug Product and Services
        7.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Pfizer Recent Developments/Updates
        7.1.6 Pfizer Competitive Strengths & Weaknesses
    7.2 Fresenius
        7.2.1 Fresenius Details
        7.2.2 Fresenius Major Business
        7.2.3 Fresenius Neuromyelitis Optica Drug Product and Services
        7.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Fresenius Recent Developments/Updates
        7.2.6 Fresenius Competitive Strengths & Weaknesses
    7.3 Teva
        7.3.1 Teva Details
        7.3.2 Teva Major Business
        7.3.3 Teva Neuromyelitis Optica Drug Product and Services
        7.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Teva Recent Developments/Updates
        7.3.6 Teva Competitive Strengths & Weaknesses
    7.4 Sandoz
        7.4.1 Sandoz Details
        7.4.2 Sandoz Major Business
        7.4.3 Sandoz Neuromyelitis Optica Drug Product and Services
        7.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Sandoz Recent Developments/Updates
        7.4.6 Sandoz Competitive Strengths & Weaknesses
    7.5 Intas
        7.5.1 Intas Details
        7.5.2 Intas Major Business
        7.5.3 Intas Neuromyelitis Optica Drug Product and Services
        7.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Intas Recent Developments/Updates
        7.5.6 Intas Competitive Strengths & Weaknesses
    7.6 Gyjtrs
        7.6.1 Gyjtrs Details
        7.6.2 Gyjtrs Major Business
        7.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Services
        7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 Gyjtrs Recent Developments/Updates
        7.6.6 Gyjtrs Competitive Strengths & Weaknesses
    7.7 NANG KUANG
        7.7.1 NANG KUANG Details
        7.7.2 NANG KUANG Major Business
        7.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Services
        7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 NANG KUANG Recent Developments/Updates
        7.7.6 NANG KUANG Competitive Strengths & Weaknesses
    7.8 Tianjin Kingyork
        7.8.1 Tianjin Kingyork Details
        7.8.2 Tianjin Kingyork Major Business
        7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Services
        7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Tianjin Kingyork Recent Developments/Updates
        7.8.6 Tianjin Kingyork Competitive Strengths & Weaknesses
    7.9 Baxter
        7.9.1 Baxter Details
        7.9.2 Baxter Major Business
        7.9.3 Baxter Neuromyelitis Optica Drug Product and Services
        7.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Baxter Recent Developments/Updates
        7.9.6 Baxter Competitive Strengths & Weaknesses
    7.10 CSL
        7.10.1 CSL Details
        7.10.2 CSL Major Business
        7.10.3 CSL Neuromyelitis Optica Drug Product and Services
        7.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 CSL Recent Developments/Updates
        7.10.6 CSL Competitive Strengths & Weaknesses
    7.11 Grifols
        7.11.1 Grifols Details
        7.11.2 Grifols Major Business
        7.11.3 Grifols Neuromyelitis Optica Drug Product and Services
        7.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Grifols Recent Developments/Updates
        7.11.6 Grifols Competitive Strengths & Weaknesses
    7.12 Octapharma
        7.12.1 Octapharma Details
        7.12.2 Octapharma Major Business
        7.12.3 Octapharma Neuromyelitis Optica Drug Product and Services
        7.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Octapharma Recent Developments/Updates
        7.12.6 Octapharma Competitive Strengths & Weaknesses
    7.13 CBOP
        7.13.1 CBOP Details
        7.13.2 CBOP Major Business
        7.13.3 CBOP Neuromyelitis Optica Drug Product and Services
        7.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 CBOP Recent Developments/Updates
        7.13.6 CBOP Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Neuromyelitis Optica Drug Industry Chain
    8.2 Neuromyelitis Optica Drug Upstream Analysis
    8.3 Neuromyelitis Optica Drug Midstream Analysis
    8.4 Neuromyelitis Optica Drug Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Neuromyelitis Optica Drug Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Neuromyelitis Optica Drug Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Neuromyelitis Optica Drug Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Neuromyelitis Optica Drug Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Neuromyelitis Optica Drug Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Neuromyelitis Optica Drug Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Neuromyelitis Optica Drug Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Neuromyelitis Optica Drug Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Neuromyelitis Optica Drug Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Neuromyelitis Optica Drug Players in 2023
    Table 12. World Neuromyelitis Optica Drug Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Neuromyelitis Optica Drug Company Evaluation Quadrant
    Table 14. Head Office of Key Neuromyelitis Optica Drug Player
    Table 15. Neuromyelitis Optica Drug Market: Company Product Type Footprint
    Table 16. Neuromyelitis Optica Drug Market: Company Product Application Footprint
    Table 17. Neuromyelitis Optica Drug Mergers & Acquisitions Activity
    Table 18. United States VS China Neuromyelitis Optica Drug Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Neuromyelitis Optica Drug Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Neuromyelitis Optica Drug Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Neuromyelitis Optica Drug Revenue Market Share (2019-2024)
    Table 23. China Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Neuromyelitis Optica Drug Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Neuromyelitis Optica Drug Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Neuromyelitis Optica Drug Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Neuromyelitis Optica Drug Revenue Market Share (2019-2024)
    Table 29. World Neuromyelitis Optica Drug Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Neuromyelitis Optica Drug Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (USD Million)
    Table 35. Pfizer Basic Information, Area Served and Competitors
    Table 36. Pfizer Major Business
    Table 37. Pfizer Neuromyelitis Optica Drug Product and Services
    Table 38. Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Pfizer Recent Developments/Updates
    Table 40. Pfizer Competitive Strengths & Weaknesses
    Table 41. Fresenius Basic Information, Area Served and Competitors
    Table 42. Fresenius Major Business
    Table 43. Fresenius Neuromyelitis Optica Drug Product and Services
    Table 44. Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. Fresenius Recent Developments/Updates
    Table 46. Fresenius Competitive Strengths & Weaknesses
    Table 47. Teva Basic Information, Area Served and Competitors
    Table 48. Teva Major Business
    Table 49. Teva Neuromyelitis Optica Drug Product and Services
    Table 50. Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. Teva Recent Developments/Updates
    Table 52. Teva Competitive Strengths & Weaknesses
    Table 53. Sandoz Basic Information, Area Served and Competitors
    Table 54. Sandoz Major Business
    Table 55. Sandoz Neuromyelitis Optica Drug Product and Services
    Table 56. Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. Sandoz Recent Developments/Updates
    Table 58. Sandoz Competitive Strengths & Weaknesses
    Table 59. Intas Basic Information, Area Served and Competitors
    Table 60. Intas Major Business
    Table 61. Intas Neuromyelitis Optica Drug Product and Services
    Table 62. Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Intas Recent Developments/Updates
    Table 64. Intas Competitive Strengths & Weaknesses
    Table 65. Gyjtrs Basic Information, Area Served and Competitors
    Table 66. Gyjtrs Major Business
    Table 67. Gyjtrs Neuromyelitis Optica Drug Product and Services
    Table 68. Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. Gyjtrs Recent Developments/Updates
    Table 70. Gyjtrs Competitive Strengths & Weaknesses
    Table 71. NANG KUANG Basic Information, Area Served and Competitors
    Table 72. NANG KUANG Major Business
    Table 73. NANG KUANG Neuromyelitis Optica Drug Product and Services
    Table 74. NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. NANG KUANG Recent Developments/Updates
    Table 76. NANG KUANG Competitive Strengths & Weaknesses
    Table 77. Tianjin Kingyork Basic Information, Area Served and Competitors
    Table 78. Tianjin Kingyork Major Business
    Table 79. Tianjin Kingyork Neuromyelitis Optica Drug Product and Services
    Table 80. Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. Tianjin Kingyork Recent Developments/Updates
    Table 82. Tianjin Kingyork Competitive Strengths & Weaknesses
    Table 83. Baxter Basic Information, Area Served and Competitors
    Table 84. Baxter Major Business
    Table 85. Baxter Neuromyelitis Optica Drug Product and Services
    Table 86. Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Baxter Recent Developments/Updates
    Table 88. Baxter Competitive Strengths & Weaknesses
    Table 89. CSL Basic Information, Area Served and Competitors
    Table 90. CSL Major Business
    Table 91. CSL Neuromyelitis Optica Drug Product and Services
    Table 92. CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. CSL Recent Developments/Updates
    Table 94. CSL Competitive Strengths & Weaknesses
    Table 95. Grifols Basic Information, Area Served and Competitors
    Table 96. Grifols Major Business
    Table 97. Grifols Neuromyelitis Optica Drug Product and Services
    Table 98. Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 99. Grifols Recent Developments/Updates
    Table 100. Grifols Competitive Strengths & Weaknesses
    Table 101. Octapharma Basic Information, Area Served and Competitors
    Table 102. Octapharma Major Business
    Table 103. Octapharma Neuromyelitis Optica Drug Product and Services
    Table 104. Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 105. Octapharma Recent Developments/Updates
    Table 106. CBOP Basic Information, Area Served and Competitors
    Table 107. CBOP Major Business
    Table 108. CBOP Neuromyelitis Optica Drug Product and Services
    Table 109. CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 110. Global Key Players of Neuromyelitis Optica Drug Upstream (Raw Materials)
    Table 111. Neuromyelitis Optica Drug Typical Customers
List of Figure
    Figure 1. Neuromyelitis Optica Drug Picture
    Figure 2. World Neuromyelitis Optica Drug Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Neuromyelitis Optica Drug Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Neuromyelitis Optica Drug Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Neuromyelitis Optica Drug Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Neuromyelitis Optica Drug Revenue (2019-2030) & (USD Million)
    Figure 13. Neuromyelitis Optica Drug Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Neuromyelitis Optica Drug Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Neuromyelitis Optica Drug by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Neuromyelitis Optica Drug Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Neuromyelitis Optica Drug Markets in 2023
    Figure 27. United States VS China: Neuromyelitis Optica Drug Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Neuromyelitis Optica Drug Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Neuromyelitis Optica Drug Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Neuromyelitis Optica Drug Market Size Market Share by Type in 2023
    Figure 31. Glucocorticoids
    Figure 32. Immunotherapies
    Figure 33. Others
    Figure 34. World Neuromyelitis Optica Drug Market Size Market Share by Type (2019-2030)
    Figure 35. World Neuromyelitis Optica Drug Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 36. World Neuromyelitis Optica Drug Market Size Market Share by Application in 2023
    Figure 37. Acute Attack
    Figure 38. Remission Prophylactic Treatment
    Figure 39. Neuromyelitis Optica Drug Industrial Chain
    Figure 40. Methodology
    Figure 41. Research Process and Data Source

Companies Mentioned

Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP